NASDAQ:ABUSArbutus Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arbutus Biopharma Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.33 +0.15 (+3.59 %) (As of 08/6/2020 02:57 PM ET) Add Compare Share Today's Range$4.26Now: $4.33▼$4.8850-Day Range$1.75MA: $2.64▼$6.2052-Week Range$0.82Now: $4.33▼$9.02Volume343,595 shsAverage Volume22.27 million shsMarket Capitalization$298.60 millionP/E RatioN/ADividend YieldN/ABeta3.25 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.80, Arbutus Biopharma has a potential upside of 31.5% from its current price of $4.41.Amount of Analyst CoverageArbutus Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesArbutus Biopharma has received 389 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArbutus Biopharma has received 299 “underperform” votes. (Add your “underperform” vote.)Community SentimentArbutus Biopharma has received 56.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote “Outperform” if you believe ABUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $100,200.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by Institutions38.12% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.87) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.74 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABUS Previous Symbol CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone267-469-0914Debt Debt-to-Equity RatioN/A Current Ratio21.91 Quick Ratio21.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.01 million Price / Sales49.68 Cash FlowN/A Price / Cash FlowN/A Book Value($1.00) per share Price / Book-4.33Profitability EPS (Most Recent Fiscal Year)($1.62) Net Income$-153,720,000.00 Net Margins-2,091.92% Return on EquityN/A Return on Assets-55.46%Miscellaneous Employees79 Outstanding Shares68,960,000Market Cap$298.60 million Next Earnings Date8/7/2020 (Confirmed) OptionableOptionable $4.33 +0.15 (+3.59 %) (As of 08/6/2020 02:57 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ABUS News and Ratings via Email Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions How has Arbutus Biopharma's stock been impacted by COVID-19 (Coronavirus)? Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 67.8% and is now trading at $4.33. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Arbutus Biopharma? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arbutus Biopharma. When is Arbutus Biopharma's next earnings date? Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Arbutus Biopharma. How can I listen to Arbutus Biopharma's earnings call? Arbutus Biopharma will be holding an earnings conference call on Friday, August 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corp (NASDAQ:ABUS) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.06. The biopharmaceutical company had revenue of $1.49 million for the quarter, compared to analysts' expectations of $1.81 million. View Arbutus Biopharma's earnings history. What price target have analysts set for ABUS? 6 brokerages have issued 12-month price objectives for Arbutus Biopharma's shares. Their forecasts range from $4.00 to $8.00. On average, they expect Arbutus Biopharma's share price to reach $5.80 in the next year. This suggests a possible upside of 33.9% from the stock's current price. View analysts' price targets for Arbutus Biopharma. Has Arbutus Biopharma been receiving favorable news coverage? Media stories about ABUS stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arbutus Biopharma earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Arbutus Biopharma. Are investors shorting Arbutus Biopharma? Arbutus Biopharma saw a increase in short interest in July. As of July 31st, there was short interest totaling 765,100 shares, an increase of 19.3% from the July 15th total of 641,200 shares. Based on an average trading volume of 6,720,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.6% of the company's shares are short sold. View Arbutus Biopharma's Current Options Chain. Who are some of Arbutus Biopharma's key competitors? Some companies that are related to Arbutus Biopharma include Supernus Pharmaceuticals (SUPN), Arvinas (ARVN), Odonate Therapeutics (ODT), Akcea Therapeutics (AKCA), Kiniksa Pharmaceuticals (KNSA), Nabriva Therapeutics (NBRV), Karyopharm Therapeutics (KPTI), Arcturus Therapeutics (ARCT), Constellation Pharmaceuticals (CNST), Esperion Therapeutics (ESPR), Humanigen (HGEN), Akero Therapeutics (AKRO), VBI Vaccines (VBIV), Retrophin (RTRX) and Arcus Biosciences (RCUS). View all competitors. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Arrowhead Pharmaceuticals (ARWR), Novavax (NVAX) and Sangamo Therapeutics (SGMO). Who are Arbutus Biopharma's key executives? Arbutus Biopharma's management team includes the following people: Dr. Mark Joseph Murray, Pres, CEO & Director (Age 70)Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 58)Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 56)Dr. Michael J. Sofia, Chief Scientific Officer (Age 61)Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 65) What is Arbutus Biopharma's stock symbol? Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS." Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Jennison Associates LLC (0.49%), UBS Group AG (0.47%), Russell Investments Group Ltd. (0.06%) and Creative Planning (0.05%). Company insiders that own Arbutus Biopharma stock include Michael J Mcelhaugh and Michael J Sofia. View institutional ownership trends for Arbutus Biopharma. Which institutional investors are selling Arbutus Biopharma stock? ABUS stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Jennison Associates LLC. View insider buying and selling activity for Arbutus Biopharma. Which institutional investors are buying Arbutus Biopharma stock? ABUS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Creative Planning. View insider buying and selling activity for Arbutus Biopharma. How do I buy shares of Arbutus Biopharma? Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arbutus Biopharma's stock price today? One share of ABUS stock can currently be purchased for approximately $4.33. How big of a company is Arbutus Biopharma? Arbutus Biopharma has a market capitalization of $298.60 million and generates $6.01 million in revenue each year. The biopharmaceutical company earns $-153,720,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe. What is Arbutus Biopharma's official website? The official website for Arbutus Biopharma is www.arbutusbio.com. How can I contact Arbutus Biopharma? Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at 267-469-0914 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
